An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of INCB018424 When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
- 06 Oct 2009 New trial record.